Clinical Trials Browser

Phase 1 × TP53 Y220C Mutation × 1 year × Clear all

NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Phase 1 Recruiting

Other solid neoplasm

TP53 Y220C Mutation